ERBB3 and neoplasm: In HER3-expressing tumors, the decreased tumor to blood ratio that was observed when 89Zr-GSK2849330 was co-injected with an increasing dose of the non-labeled GSK2849330 was presumably a result of in-vivo competition for the HER3 binding sites.